Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) have earned an average rating of “Hold” from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.00.
Several equities research analysts have commented on the company. Cowen reissued an “outperform” rating on shares of Five Prime Therapeutics in a report on Wednesday, August 12th. Wedbush upgraded Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $5.00 to $9.00 in a research report on Monday, June 22nd. ValuEngine upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 11th. Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, BidaskClub raised Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th.
Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter valued at about $36,000. Virtu Financial LLC purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter valued at about $91,000. State of Wisconsin Investment Board purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter valued at about $109,000. Public Employees Retirement System of Ohio purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter valued at about $118,000. Finally, Bank of America Corp DE increased its stake in shares of Five Prime Therapeutics by 18.5% in the 2nd quarter. Bank of America Corp DE now owns 20,963 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 3,274 shares in the last quarter. Hedge funds and other institutional investors own 68.02% of the company’s stock.
Shares of FPRX traded down $0.19 during trading hours on Friday, reaching $4.59. 4,943 shares of the company’s stock traded hands, compared to its average volume of 305,127. The stock has a market cap of $169.04 million, a PE ratio of -1.55 and a beta of 2.92. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.36. Five Prime Therapeutics has a 12 month low of $1.75 and a 12 month high of $7.34. The firm’s 50 day simple moving average is $5.93 and its 200-day simple moving average is $4.45.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.22. Five Prime Therapeutics had a negative return on equity of 71.64% and a negative net margin of 579.41%. As a group, analysts expect that Five Prime Therapeutics will post -2.33 earnings per share for the current fiscal year.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Story: The risks of owning bonds
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.